PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
Anticancer Research · 2024
DOI: 10.21873/anticanres.17279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Insu Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, B7-H1 Antigen, Lung Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
- Department of Internal Medicine, School of Medicine, Keimyung University, Busan, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
- Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Zitieren
APA
Kim, I., Choi, S. H., Lee, S. Y., Yoo, S. S., Park, J. E., Shin, K. C., Jang, J. G., Hong, K. S., Kwon, Y. S., Park, S. H., Choi, K. J., Jung, C. Y., Kim, M. H., Kim, S. H., Seol, H. Y., Kim, J., Park, J. H., Kim, T. H., Eom, J. S., & Ahn, J. H. (2024). PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Anticancer Research. https://doi.org/10.21873/anticanres.17279
Vancouver
Kim I, Choi SH, Lee SY, Yoo SS, Park JE, Shin KC, et al. PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Anticancer Research. 2024. doi:10.21873/anticanres.17279
BibTeX
@article{Kim2024,
author = {Kim, Insu and Choi, Sun Ha and Lee, Shin Yup and Yoo, Seung Soo and Park, Ji Eun and Shin, Kyeong-Cheol and Jang, Jong Geol and Hong, Kyung Soo and Kwon, Yong Shik and Park, Sun Hyo and Choi, Keum-Ju and Jung, Chi Young and Kim, Mi-Hyun and Kim, Soo Han and Seol, Hee Yun and Kim, Jehun and Park, Jin-Han and Kim, Tae Hoon and Eom, Jung Seop and Ahn, June Hong},
title = {PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17279}
}
EUVIMED